Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Guyer

Showing results (181-190 of 182) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 182 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2013
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimenR Campo, E DeJesus, U F Bredeek, et al.
HIV Clinical Trials|July 10, 2013
Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE StudiesM R Nelson, R A Elion, C J Cohen, et al.
Pageof 19

Showing results (181-190 of 182) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 182 results.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 31, 2013
SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimenR Campo, E DeJesus, U F Bredeek, et al.
HIV Clinical Trials|July 10, 2013
Rilpivirine versus efavirenz in HIV-1-infected subjects receiving emtricitabine/tenofovir DF: pooled 96-week data from ECHO and THRIVE StudiesM R Nelson, R A Elion, C J Cohen, et al.
Pageof 19